Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: A population-based study

Respirology

Volumn 15, Issue 3, 2010, Pages 530-535

  ÓlafsdÓttir, Inga S ^a   Janson, Christer ^a   Lind, Lars ^b   Hulthe, Johannes ^c   GunnbjÖrnsdÓttir, María ^c   SundstrÖm, Johan ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Age; Gender; Lung function; Matrix metalloproteinase 9; Tissue inhibitor of metalloproteinase 1

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SPIROMETRY;

AGED; AGING; EXTRACELLULAR MATRIX; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MATRIX METALLOPROTEINASE 9; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; SPIROMETRY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77950211818     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01718.x     Document Type: Article

References (38)

1. Tetley TD. New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax 1993 48 : 560 565.
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001 17 : 463 516.
3. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006 61 : 259 266.
4. Finlay GA, O'Driscoll LR, Russell KJ et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. 1997 156 : 240 247.
5. Senior RM, Griffin GL, Fliszar CJ et al. Human 92- and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 1991 266 : 7870 7875.
6. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002 121 : 156S 9S.
7. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000 1477 : 267 283.
8. Bosse M, Chakir J, Rouabhia M et al. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 1999 159 : 596 602.
9. Beeh KM, Beier J, Kornmann O et al. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir. Med. 2003 97 : 634 639.
10. Higashimoto Y, Yamagata Y, Iwata T et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur. Respir. J. 2005 25 : 885 890.
11. Vignola AM, Riccobono L, Mirabella A et al. Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 1998 158 : 1945 1950.
12. Lind L, Fors N, Hall J et al. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler. Thromb. Vasc. Biol. 2005 25 : 2368 2375.
13. Engstrom G, Gerhardsson de Verdier M, Dahlbäck M et al. BP variability and cardiovascular autonomic function in relation to forced expiratory volume: a population-based study. Chest 2009 136 : 177 183.
14. American Thoracic Society. Standardization of spirometry, 1994 update. Am. J. Respir. Crit. Care. Med. 1995 152 : 1107 1136.
15. European Community for Coal Steel. Standardisation of lung function tests. Clin. Respir. Phys. 1983 19 (Suppl. 5 22 7.
16. Aldonyte R, Eriksson S, Piitulainen E et al. Analysis of systemic biomarkers in COPD patients. COPD 2004 1 : 155 164.
17. Kang MJ, Oh YM, Lee JC et al. Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. J. Korean Med. Sci. 2003 18 : 821 827.
18. Hautamaki RD, Kobayashi DK, Senior RM et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997 277 : 2002 2004.
19. Russell RE, Culpitt SV, DeMatos C et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2002 26 : 602 609.
20. Ohnishi K, Takagi M, Kurokawa Y et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. 1998 78 : 1077 1087.
21. Imai K, Dalal SS, Chen ES et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am. J. Respir. Crit. Care Med. 2001 163 : 786 791.
22. Segura-Valdez L, Pardo A, Gaxiola M et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000 117 : 684 694.
23. Vernooy JH, Lindeman JH, Jacobs JA et al. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004 126 : 1802 1810.
24. Ólafsdóttir I, Gíslason T, Thjódleifsson B et al. Gender differences in the association between C-reactive protein, lung function impairment and COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2007 2 : 635 642.
25. Thorleifsson SJ, Margretardottir OB, Gudmundsson G et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir. Med. 2009 103 : 1548 1553.
26. Blum CA, Muller B, Huber P et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J. Clin. Endocrinol. Metab. 2005 90 : 3230 3235.
27. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J. Clin. Endocrinol. Metab. 2003 88 : 2470 2478.
28. Martinez FJ, Curtis JL, Sciurba F et al. Sex differences in severe pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2007 176 : 243 252.
29. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007 62 : 237 241.
30. Kosmala W, Plaksej R, Przewlocka-Kosmala M et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int. J. Obes. (Lond). 2008 32 : 763 771.
31. Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007 56 : 799 805.
32. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005 127 : 1952 1959.
33. Engstrom G, Hedblad B, Janzon L. Reduced lung function predicts increased fatality in future cardiac events. A population-based study. J. Intern. Med. 2006 260 : 560 567.
34. Sundstrom J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr. Opin. Lipidol. 2006 17 : 45 53.
35. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004 109 : 2850 2856.
36. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J. 2004 25 : 1509 1516.
37. Lowrey GE, Henderson N, Blakey JD et al. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir. Med. 2008 102 : 845 851.
38. Rouy D, Ernens I, Jeanty C et al. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal. Biochem. 2005 338 : 294 298.